{"id":62121,"date":"2026-04-01T21:33:37","date_gmt":"2026-04-01T13:33:37","guid":{"rendered":"https:\/\/flcube.com\/?p=62121"},"modified":"2026-04-01T21:33:40","modified_gmt":"2026-04-01T13:33:40","slug":"sanofi-secures-eu-conditional-approval-for-rezurock-in-chronic-graft-versus-host-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62121","title":{"rendered":"Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease"},"content":{"rendered":"\n<p><strong>Sanofi<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/SNY:NASDAQ\">NASDAQ: SNY<\/a>) announced that the <strong>European Commission (EC)<\/strong> has granted <strong>conditional marketing authorization<\/strong> for <strong>Rezurock (belumosudil)<\/strong> for the treatment of <strong>chronic graft-versus-host disease (cGVHD)<\/strong> in adult and pediatric patients aged <strong>12 years and older weighing at least 40 kg<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-approval-details\">Regulatory Approval Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Authority<\/strong><\/td><td>European Commission (EC)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Conditional marketing authorization<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Rezurock (belumosudil)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Chronic graft-versus-host disease (cGVHD)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Adults and pediatric patients \u226512 years, \u226540 kg<\/td><\/tr><tr><td><strong>Orphan Designation<\/strong><\/td><td>Maintained (originally granted 2019)<\/td><\/tr><tr><td><strong>Supporting Evidence<\/strong><\/td><td>Phase II ROCKstar study + real-world evidence<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-rockstar-study\">Clinical Evidence \u2013 ROCKstar Study<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-study-design\">Study Design<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Trial ID<\/strong>: NCT03640481<\/li>\n\n\n\n<li><strong>Design<\/strong>: Randomized, multicenter Phase II<\/li>\n\n\n\n<li><strong>Population<\/strong>: cGVHD patients post-stem cell transplantation<\/li>\n\n\n\n<li><strong>Prior Therapy<\/strong>: At least two prior lines of systemic therapy<\/li>\n\n\n\n<li><strong>Primary Endpoint<\/strong>: Overall response rate<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-results\">Key Results<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Efficacy<\/strong>: Clinically meaningful and durable responses<\/li>\n\n\n\n<li><strong>Safety<\/strong>: Overall favorable tolerability profile<\/li>\n\n\n\n<li><strong>Significance<\/strong>: Addresses critical unmet need in heavily pre-treated cGVHD population<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule<\/strong>: Belumosudil \u2013 selective ROCK2 inhibitor<\/li>\n\n\n\n<li><strong>Target<\/strong>: Rho-associated coiled-coil kinase 2 (ROCK2)<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Modulates immune response and reduces fibrosis in cGVHD<\/li>\n\n\n\n<li><strong>Development Status<\/strong>: First-in-class selective ROCK2 inhibitor for cGVHD<\/li>\n\n\n\n<li><strong>Orphan Status<\/strong>: Orphan designation confirmed by EMA&#8217;s COMP committee<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-strategic-significance\">Market Opportunity &amp; Strategic Significance<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-cgvhd-treatment-landscape\">cGVHD Treatment Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence<\/strong>: Affects 30-70% of allogeneic stem cell transplant recipients<\/li>\n\n\n\n<li><strong>Current Standard<\/strong>: Limited treatment options with corticosteroids as first-line<\/li>\n\n\n\n<li><strong>Unmet Need<\/strong>: High morbidity and mortality in refractory cGVHD patients<\/li>\n\n\n\n<li><strong>Treatment Gap<\/strong>: Few approved therapies for patients failing multiple prior treatments<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-commercial-implications\">Commercial Implications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Exclusivity<\/strong>: Orphan designation provides 10 years of market protection in EU<\/li>\n\n\n\n<li><strong>Pricing Power<\/strong>: Premium pricing expected for novel mechanism in orphan indication<\/li>\n\n\n\n<li><strong>Competitive Position<\/strong>: Differentiated mechanism versus existing immunosuppressants<\/li>\n\n\n\n<li><strong>Global Strategy<\/strong>: EU approval supports ongoing regulatory submissions worldwide<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-pathway-amp-next-steps\">Regulatory Pathway &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Conditional Authorization<\/strong>: Requires post-marketing confirmatory studies<\/li>\n\n\n\n<li><strong>Orphan Maintenance<\/strong>: COMP committee formally confirmed continued orphan status<\/li>\n\n\n\n<li><strong>Launch Timeline<\/strong>: Expected commercial availability in major EU markets within 6-12 months<\/li>\n\n\n\n<li><strong>Additional Submissions<\/strong>: Ongoing regulatory reviews in other global markets<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-impact-for-sanofi\">Strategic Impact for Sanofi<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immunology Franchise<\/strong>: Strengthens position in immune-mediated diseases<\/li>\n\n\n\n<li><strong>Oncology Adjacent<\/strong>: Expands presence in stem cell transplant complications<\/li>\n\n\n\n<li><strong>Rare Disease Focus<\/strong>: Aligns with strategic emphasis on orphan indications<\/li>\n\n\n\n<li><strong>Revenue Diversification<\/strong>: New high-value specialty product with premium pricing potential<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, commercial launch, and market potential for Rezurock. Actual results may differ due to risks including post-marketing study requirements, competitive dynamics, and market adoption.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi (NASDAQ: SNY) announced that the European Commission (EC) has granted conditional marketing authorization for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":62123,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,867,15,147],"class_list":["post-62121","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-auto-immune","tag-nasdaq-sny","tag-product-approvals","tag-sanofi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sanofi (NASDAQ: SNY) announced that the European Commission (EC) has granted conditional marketing authorization for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (cGVHD) in adult and pediatric patients aged 12 years and older weighing at least 40 kg.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62121\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease\" \/>\n<meta property=\"og:description\" content=\"Sanofi (NASDAQ: SNY) announced that the European Commission (EC) has granted conditional marketing authorization for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (cGVHD) in adult and pediatric patients aged 12 years and older weighing at least 40 kg.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62121\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-01T13:33:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-01T13:33:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0104.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62121#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62121\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease\",\"datePublished\":\"2026-04-01T13:33:37+00:00\",\"dateModified\":\"2026-04-01T13:33:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62121\"},\"wordCount\":400,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62121#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0104.webp\",\"keywords\":[\"Auto-immune\",\"NASDAQ: SNY\",\"Product approvals\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62121#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62121\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62121\",\"name\":\"Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62121#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62121#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0104.webp\",\"datePublished\":\"2026-04-01T13:33:37+00:00\",\"dateModified\":\"2026-04-01T13:33:40+00:00\",\"description\":\"Sanofi (NASDAQ: SNY) announced that the European Commission (EC) has granted conditional marketing authorization for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (cGVHD) in adult and pediatric patients aged 12 years and older weighing at least 40 kg.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62121#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62121\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62121#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0104.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0104.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62121#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease - Insight, China&#039;s Pharmaceutical Industry","description":"Sanofi (NASDAQ: SNY) announced that the European Commission (EC) has granted conditional marketing authorization for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (cGVHD) in adult and pediatric patients aged 12 years and older weighing at least 40 kg.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62121","og_locale":"en_US","og_type":"article","og_title":"Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease","og_description":"Sanofi (NASDAQ: SNY) announced that the European Commission (EC) has granted conditional marketing authorization for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (cGVHD) in adult and pediatric patients aged 12 years and older weighing at least 40 kg.","og_url":"https:\/\/flcube.com\/?p=62121","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-01T13:33:37+00:00","article_modified_time":"2026-04-01T13:33:40+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0104.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62121#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62121"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease","datePublished":"2026-04-01T13:33:37+00:00","dateModified":"2026-04-01T13:33:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62121"},"wordCount":400,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=62121#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0104.webp","keywords":["Auto-immune","NASDAQ: SNY","Product approvals","Sanofi"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62121#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62121","url":"https:\/\/flcube.com\/?p=62121","name":"Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=62121#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=62121#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0104.webp","datePublished":"2026-04-01T13:33:37+00:00","dateModified":"2026-04-01T13:33:40+00:00","description":"Sanofi (NASDAQ: SNY) announced that the European Commission (EC) has granted conditional marketing authorization for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (cGVHD) in adult and pediatric patients aged 12 years and older weighing at least 40 kg.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62121#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62121"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=62121#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0104.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0104.webp","width":1080,"height":608,"caption":"Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62121#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0104.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62121"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62121\/revisions"}],"predecessor-version":[{"id":62124,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62121\/revisions\/62124"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/62123"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}